NUTEX HEALTH INC (NUTX) Fundamental Analysis & Valuation

NASDAQ:NUTX • US67079U3068

Current stock price

101.05 USD
-4.65 (-4.4%)
At close:
101.05 USD
0 (0%)
After Hours:

This NUTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. NUTX Profitability Analysis

1.1 Basic Checks

  • NUTX had positive earnings in the past year.
  • NUTX had a positive operating cash flow in the past year.
  • In multiple years NUTX reported negative net income over the last 5 years.
  • NUTX had a positive operating cash flow in 4 of the past 5 years.
NUTX Yearly Net Income VS EBIT VS OCF VS FCFNUTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • NUTX has a better Return On Assets (6.99%) than 86.00% of its industry peers.
  • NUTX has a better Return On Equity (19.49%) than 87.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 28.16%, NUTX belongs to the top of the industry, outperforming 99.00% of the companies in the same industry.
Industry RankSector Rank
ROA 6.99%
ROE 19.49%
ROIC 28.16%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NUTX Yearly ROA, ROE, ROICNUTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • NUTX's Profit Margin of 7.34% is amongst the best of the industry. NUTX outperforms 86.00% of its industry peers.
  • NUTX's Operating Margin of 30.53% is amongst the best of the industry. NUTX outperforms 99.00% of its industry peers.
  • With a decent Gross Margin value of 50.76%, NUTX is doing good in the industry, outperforming 77.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NUTX has grown nicely.
Industry RankSector Rank
OM 30.53%
PM (TTM) 7.34%
GM 50.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y102.27%
GM growth 5Y3.56%
NUTX Yearly Profit, Operating, Gross MarginsNUTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. NUTX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NUTX is creating value.
  • There is no outstanding debt for NUTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NUTX Yearly Shares OutstandingNUTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
NUTX Yearly Total Debt VS Total AssetsNUTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • NUTX has an Altman-Z score of 2.72. This is not the best score and indicates that NUTX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • NUTX has a better Altman-Z score (2.72) than 63.00% of its industry peers.
  • The Debt to FCF ratio of NUTX is 1.32, which is an excellent value as it means it would take NUTX, only 1.32 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.32, NUTX belongs to the top of the industry, outperforming 83.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.91 indicates that NUTX is somewhat dependend on debt financing.
  • NUTX's Debt to Equity ratio of 0.91 is in line compared to the rest of the industry. NUTX outperforms 44.00% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for NUTX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF 1.32
Altman-Z 2.72
ROIC/WACC3.53
WACC7.97%
NUTX Yearly LT Debt VS Equity VS FCFNUTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • NUTX has a Current Ratio of 3.41. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NUTX (3.41) is better than 86.00% of its industry peers.
  • A Quick Ratio of 3.39 indicates that NUTX has no problem at all paying its short term obligations.
  • NUTX has a better Quick ratio (3.39) than 86.00% of its industry peers.
Industry RankSector Rank
Current Ratio 3.41
Quick Ratio 3.39
NUTX Yearly Current Assets VS Current LiabilitesNUTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NUTX Growth Analysis

3.1 Past

  • NUTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.24%.
  • Looking at the last year, NUTX shows a very strong growth in Revenue. The Revenue has grown by 82.36%.
  • The Revenue has been growing by 253.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.44%
Revenue 1Y (TTM)82.36%
Revenue growth 3Y58.62%
Revenue growth 5Y253.48%
Sales Q2Q%-41.12%

3.2 Future

  • NUTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.52% yearly.
  • The Revenue is expected to decrease by -1.79% on average over the next years.
EPS Next Y135.38%
EPS Next 2Y70.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.41%
Revenue Next 2Y-1.79%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NUTX Yearly Revenue VS EstimatesNUTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
NUTX Yearly EPS VS EstimatesNUTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 20 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

9

4. NUTX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.10 indicates a reasonable valuation of NUTX.
  • Based on the Price/Earnings ratio, NUTX is valued cheaper than 89.00% of the companies in the same industry.
  • NUTX is valuated cheaply when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 4.72, the valuation of NUTX can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 98.00% of the companies listed in the same industry.
  • NUTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.1
Fwd PE 4.72
NUTX Price Earnings VS Forward Price EarningsNUTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NUTX is valued cheaper than 98.00% of the companies in the same industry.
  • NUTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NUTX is cheaper than 98.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.92
EV/EBITDA 3.02
NUTX Per share dataNUTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • NUTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NUTX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NUTX's earnings are expected to grow with 70.52% in the coming years.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y70.52%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NUTX Dividend Analysis

5.1 Amount

  • No dividends for NUTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUTX Fundamentals: All Metrics, Ratios and Statistics

NUTEX HEALTH INC

NASDAQ:NUTX (4/10/2026, 8:00:01 PM)

After market: 101.05 0 (0%)

101.05

-4.65 (-4.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-05
Earnings (Next)05-11
Inst Owners38.08%
Inst Owner Change0%
Ins Owners2.39%
Ins Owner Change0%
Market Cap704.32M
Revenue(TTM)875.26M
Net Income(TTM)64.21M
Analysts82.22
Price Target226.1 (123.75%)
Short Float %19.4%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.28
Dividend Growth(5Y)N/A
DP115.68%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)261.38%
Min EPS beat(2)-75.2%
Max EPS beat(2)597.97%
EPS beat(4)2
Avg EPS beat(4)132.9%
Min EPS beat(4)-75.2%
Max EPS beat(4)597.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-9.87%
Min Revenue beat(2)-42.54%
Max Revenue beat(2)22.8%
Revenue beat(4)3
Avg Revenue beat(4)16.11%
Min Revenue beat(4)-42.54%
Max Revenue beat(4)76.42%
Revenue beat(8)7
Avg Revenue beat(8)36.59%
Revenue beat(12)7
Avg Revenue beat(12)23.1%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.33%
PT rev (3m)-11.33%
EPS NQ rev (1m)-1.79%
EPS NQ rev (3m)-1.79%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-6.9%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)-8.78%
Revenue NY rev (3m)-8.78%
Valuation
Industry RankSector Rank
PE 11.1
Fwd PE 4.72
P/S 0.8
P/FCF 2.92
P/OCF 2.84
P/B 2.14
P/tB 2.39
EV/EBITDA 3.02
EPS(TTM)9.1
EY9.01%
EPS(NY)21.42
Fwd EY21.2%
FCF(TTM)34.62
FCFY34.26%
OCF(TTM)35.6
OCFY35.23%
SpS125.57
BVpS47.27
TBVpS42.22
PEG (NY)0.08
PEG (5Y)N/A
Graham Number98.38
Profitability
Industry RankSector Rank
ROA 6.99%
ROE 19.49%
ROCE 35.13%
ROIC 28.16%
ROICexc 37.24%
ROICexgc 39.66%
OM 30.53%
PM (TTM) 7.34%
GM 50.76%
FCFM 27.57%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y102.27%
GM growth 5Y3.56%
F-Score8
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF 1.32
Debt/EBITDA 1.04
Cap/Depr 33.31%
Cap/Sales 0.78%
Interest Coverage 106.53
Cash Conversion 86.24%
Profit Quality 375.8%
Current Ratio 3.41
Quick Ratio 3.39
Altman-Z 2.72
F-Score8
WACC7.97%
ROIC/WACC3.53
Cap/Depr(3y)33.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.7%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.44%
EPS Next Y135.38%
EPS Next 2Y70.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)82.36%
Revenue growth 3Y58.62%
Revenue growth 5Y253.48%
Sales Q2Q%-41.12%
Revenue Next Year-5.41%
Revenue Next 2Y-1.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y94.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1057.25%
FCF growth 3Y88.59%
FCF growth 5YN/A
OCF growth 1Y971.63%
OCF growth 3Y69.88%
OCF growth 5YN/A

NUTEX HEALTH INC / NUTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NUTEX HEALTH INC (NUTX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to NUTX.


What is the valuation status of NUTEX HEALTH INC (NUTX) stock?

ChartMill assigns a valuation rating of 9 / 10 to NUTEX HEALTH INC (NUTX). This can be considered as Undervalued.


How profitable is NUTEX HEALTH INC (NUTX) stock?

NUTEX HEALTH INC (NUTX) has a profitability rating of 6 / 10.


How financially healthy is NUTEX HEALTH INC?

The financial health rating of NUTEX HEALTH INC (NUTX) is 8 / 10.


Can you provide the dividend sustainability for NUTX stock?

The dividend rating of NUTEX HEALTH INC (NUTX) is 0 / 10 and the dividend payout ratio is 115.68%.